Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

• Status: Active, not recruiting
• Trial end date: 2023-12-01

Summary

The purpose of this research study is to determine the safety of CT-011 alone, as well as the combination of the Dendritic cell fusion vaccine and CT-011, after autologous stem cell transplantation (ASCT). We are also trying to find out what effect the combination has on the disease, including if it is more successful in preventing or delaying the disease from coming back, compared to treatment with autologous transplantation alone. ASCT is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer in the body. CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug given by infusion into a vein and are known to target specific cells (in this case, cells in the immune system). The dendritic cell fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. Unlike a standard vaccine that is used to prevent infections, cancer vaccines are being studied to see if they can fight cancers that are already in the body.

• Phase: Phase 2

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborators: Brigham and Women's Hospital; Dana-Farber Cancer Institute; Gateway for Cancer Research; Rambam Health Care Campus; United States Department of Defense
• Treatments: Pidilizumab; Polystyrene sulfonic acid; Vaccines